You can now read 10 articles each month for free on

The Boston Globe


Watson Pharma.

Continue reading below

Reports last week suggested that drug maker Watson Pharmaceuticals Inc. is in talks to buy European counterpart Actavis. Citing unidentified sources, Reuters said the Parsippany, N.J., company could pay up to $7.3 billion for privately held Actavis. Both companies declined to comment. In May, Watson bought generics maker Specifar Pharmaceuticals of Greece in a deal valued at $563.1 million.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week